Breast Cancer Clinical Trials in Sacramento, CA

45 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)	Phase 3	Gilead Sciences	<1 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab	Phase 3	Alliance for Clinical Trials in Oncology	<1 mi
E-Mindfulness Approaches for Living After Breast Cancer	Phase 3	NRG Oncology	<1 mi
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer	Phase 3	NRG Oncology	<1 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors	N/A	NRG Oncology	<1 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer	N/A	SWOG Cancer Research Network	<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25	Phase 3	NRG Oncology	<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)	Phase 3	NRG Oncology	<1 mi
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity	Phase 3	SWOG Cancer Research Network	<1 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer	Phase 3	SWOG Cancer Research Network	<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection	—	Alliance for Clinical Trials in Oncology	<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics	—	Wake Forest University Health Sciences	<1 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer	Phase 3	Canadian Cancer Trials Group	<1 mi
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials	N/A	Eastern Cooperative Oncology Group	<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab	Phase 3	Alliance for Clinical Trials in Oncology	<1 mi
Mobile Health for Adherence in Breast Cancer Patients	N/A	ECOG-ACRIN Cancer Research Group	<1 mi
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Phase 2	National Cancer Institute (NCI)	<1 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Phase 3	National Cancer Institute (NCI)	<1 mi
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies	Early 1	Presage Biosciences	<1 mi
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Phase 3	AstraZeneca	<1 mi
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	Phase 1	National Cancer Institute (NCI)	<1 mi
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)	Phase 3	DualityBio Inc.	<1 mi
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)	Phase 3	Hoffmann-La Roche	<1 mi
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)	N/A	University of California, San Francisco	<1 mi
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence	Phase 3	Stemline Therapeutics, Inc.	<1 mi
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer	Phase 3	Novartis Pharmaceuticals	<1 mi
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer	Phase 2	National Cancer Institute (NCI)	<1 mi
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease	Phase 3	Pfizer	<1 mi
The PREDICT Registry:	—	PreludeDx	<1 mi
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)	Phase 1	University of California, Davis	<1 mi
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy	Phase 2	Eve Rodler	<1 mi
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)	N/A	University of California, Davis	<1 mi
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer	Phase 1	National Cancer Institute (NCI)	<1 mi
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies	Phase 1	Janux Therapeutics	<1 mi
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Phase 1	Clasp Therapeutics, Inc.	<1 mi
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation	—	Guardant Health, Inc.	<1 mi
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors	Phase 1	University of California, Davis	<1 mi
A Study of DB-1310 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	<1 mi
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors	Phase 1	Seagen, a wholly owned subsidiary of Pfizer	<1 mi
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	Phase 2	QuantumLeap Healthcare Collaborative	14 mi
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)	Phase 3	Eli Lilly and Company	16 mi
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)	Phase 3	Merck Sharp & Dohme LLC	16 mi
BostonGene and Exigent Genomic INsight Study	—	BostonGene	45 mi
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)	Phase 3	AstraZeneca	47 mi
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain	Phase 3	NRG Oncology	47 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.